|
Austria-Ru-Ru Azienda Directories
|
Azienda News:
- Treatment of psoriasis - DermNet
Localised treatment is commonly used to treat thick plaques or moderate-to-severe hand and or foot psoriasis, including palmoplantar pustulosis Photosensitivity persists for some hours following oral psoralen treatment; therefore, patients are advised to avoid sun exposure, including wearing wrap-around sunglasses on the day of treatment
- Psoriasis: Symptoms, Treatment, Images and More - DermNet
Most psoriasis centres offer phototherapy (light therapy) with ultraviolet (UV) radiation, often in combination with topical or systemic agents, including: UVB phototherapy; PUVA (photochemotherapy) Targeted phototherapy; Excimer laser Systemic therapy Moderate to severe psoriasis warrants treatment with a systemic agent and or phototherapy
- Chronic Plaque Psoriasis: Causes, Symptoms, and Treatment - DermNet
A meta-analysis of systemic pharmacological treatment for chronic plaque psoriasis found that compared to placebo, biologic agents infliximab, bimekizumab, ixekizumab, and risankizumab were the most effective in achieving 90% improvement in PASI score from baseline at 6 months follow up in patients with moderate to severe psoriasis
- Guidelines for the management of psoriasis - DermNet
The eligibility criteria include having 'whole body' severe chronic plaque psoriasis with a PASI score of > 10 (> 15 for infliximab) or severe chronic plaque psoriasis of the face, palm or sole The patient must also have had psoriasis for greater than 6 months and have trialled (or have contraindications to) at least three of the following
- Facial psoriasis - DermNet
Tacrolimus ointment for the treatment of severe facial plaque psoriasis J Eur Acad Dermatol Venereol 2005 Mar;19(2):249–51 PubMed; Hashim PW, Chima M, Kim HJ, et al Crisaborole 2% ointment for the treatment of intertriginous, anogenital, and facial psoriasis: a double-blind, randomized, vehicle-controlled trial
- Adalimumab for psoriasis - DermNet
In September 2015, the FDA also approved adalimumab for the treatment of hidradenitis suppurativa In New Zealand (October 2019), PHARMAC has approved funding on Special Authority application in certain circumstances for severe treatment-resistant psoriasis, moderate to severe hidradenitis suppurativa, Behcet syndrome and pyoderma gangrenosum
- Scalp Psoriasis: A Complete Overview - DermNet
Direct treatment may be helped by a handheld ultraviolet B (UVB) comb device Systemic agents Consider first-line for patients with scalp psoriasis and accompanying moderate-to-severe whole-body psoriasis; and second-line in other cases where there has been an inadequate response to topical therapy
- Deucravacitinib: A Complete Overview - DermNet
Thaçi D, Strober B, Gordon KB, et al Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial Dermatol Ther (Heidelb) 2022;12(2):495–510 doi: 10 1007 s13555-021-00649-y Journal; On DermNet Chronic plaque psoriasis; Psoriasis; Janus kinase inhibitors; Immunisation in immunosuppressed
- Biological agents for psoriasis - DermNet
In New Zealand, infliximab, adalimumab, etanercept and secukinumab are funded by PHARMAC for some cases of severe psoriasis on Special Authority application Vaccinations and biological agents Immunisation status should be reviewed prior to starting treatment with biological agents If necessary, vaccines should be updated prior to treatment
- Treatment of psoriasis in pregnancy - DermNet
For many pregnant women (33–60%), psoriasis improves during pregnancy but for a minority the disease may flare (25%) In the postpartum period, flaring of psoriasis is common (65%) The severity of psoriasis during pregnancy can improve during pregnancy (40–60%), worsen (10–20%), or remain stable in the remainder
|
|